acquisition of a majority stake in ATI Physical Therapy Holdings, LLC, a provider of outpatient rehabilitation services, including physical therapy and work conditioning, from KRG Capital Partners.
as a member of a consortium, in the consortium’s approximately $3.3 billion take-private of Wuxi PharmaTech, a global contract R&D services provider serving the pharmaceutical and biotechnology industries.
- $5.4 billion acquisition of the animal health business of Novartis AG
- $960 million acquisition of CoLucid Pharmaceuticals, Inc.
- $410 million sale of veterinary assets to Virbac SA
- acquisition by Elanco, its animal health division, of Lohmann SE, a supplier of poultry vaccines and feed additives
- antitrust aspects of a joint venture with DEKA to develop a novel subcutaneous insulin pump
$7.6 billion sale to Community Health Systems, Inc.
$17.6 billion all-stock merger of equals with Quintiles Transnational Holdings Inc.
$4.6 billion merger with INC Research Holdings, Inc.
and its portfolio company National Surgical Hospitals, Inc. (d/b/a National Surgical Healthcare) in its $760 million sale to Surgery Partners, Inc.
$2.6 billion sale to Valeant Pharmaceuticals International. We also advised on all of the antitrust-related aspects of the acquisition. Weil’s representation of Medicis in the Valeant deal was featured in Law360’s “Sealing the Deal,” which describes the extraordinary 10-day turnaround of the deal. “Having past experience with Medicis gave the attorneys important insight into the company’s sticking points and interests. A deep familiarity with the company’s priorities meant [Matthew] Gilroy had an edge in negotiating the deal quickly: he knew where his focus should be, what to compromise and what to decide.”
€1.8 billion sale of its majority stake in Cerba HealthCare (f/k/a Cerba European Lab) to Partners Group and Public Sector Pension Investment Board.
- acquisition of Aegerion Pharmaceuticals, Inc.
- minority investment in Aralez Pharmaceuticals Plc and distribution of the acquired Aralez shares to its shareholders
- $25 billion exchange of Merial, its animal health business, for the consumer healthcare business of Boehringer Ingelheim GmbH
- $20.1 billion takeover of Genzyme, a biotechnology firm
- in its $11.6 billion acquisition of Bioverativ Inc.
- in its pending $4.8 billion acquisition of Ablynx NV
- in its up to $750 million acquisition of Protein Sciences Corporation
- in, together with Third Rock Ventures and Greylock Partners, its investment in Warp Drive Bio, a start-up focusing on proprietary genomic technology to discover drugs of natural origin
- worldwide exclusive licensing agreement with MannKind Corporation to develop and commercialize Afrezza® (insulin human) Inhalation Powder
- antitrust aspects of its $21 billion acquisition of Pharmacyclics, Inc., a biopharmaceutical company
- antitrust aspects of its $5.8 billion acquisition of Stemcentrx Inc., a developer of oncology compounds targeting various types of solid tumor cancers
- antitrust aspects of its $70.5 billion acquisition of Allergan, Inc., a multi-specialty health care company that developed and commercialized pharmaceutical, biological, medical device and over-the-counter products
- antitrust aspects of its $600 million sale of its Branded Respiratory Portfolio to AstraZeneca
- antitrust aspects of its $39 billion sale of its global generic pharmaceuticals business to Teva Pharmaceutical Industries Ltd., one of the most complex pharmaceutical mergers ever reviewed by the FTC
- antitrust aspects of its $2.9 billion acquisition of LifeCell Corporation, a developer and marketer of tissue repair products for use in reconstructive, urogynecologic, and orthopedic surgical procedures
- antitrust aspects of its $2.47 billion acquisition of Zeltiq Aesthetics Inc., a medical technology company that developed and commercialized products using a proprietary controlled-cooling technology platform
- antitrust aspects of its $2.1 billion acquisition of KYTHERA Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on novel prescription products in aesthetic medicine
- in its challenge of the Novartis/GSK Oncology transaction, successfully persuading regulators in both the U.S. and the E.U. that the transaction had anticompetitive effects and required a remedy – and that Array was a suitable divestiture buyer for the divested assets
- antitrust aspects of its $13.4 billion acquisition by Zimmer Holdings, Inc., a manufacturer of orthopedic reconstructive, dental and spinal implants, and trauma and related surgical products
- antitrust aspects of its $24.2 billion acquisition by Actavis, Inc.
- antitrust aspects of its $2.9 billion acquisition of Aptalis Pharma, Inc., a developer of products for the treatment of gastrointestinal diseases and cystic fibrosis
- antitrust aspects of its $21.3 billion acquisition of Swiss-American orthopedic devices maker Synthes Inc., with Weil negotiating a limited divestiture in order to obtain antitrust clearance
- antitrust aspects of its $4.3 billion acquisition of Abbott Medical Optics (AMO)
- antitrust aspects of its $2 billion sale of its Cordis business, a developer and manufacturer of interventional vascular technology, to Cardinal Health, Inc.
- antitrust aspects of its acquisition of Novira Therapeutics Inc., a clinical-stage biopharmaceutical developer of novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection
- antitrust aspects of its proposed $5.175 billion acquisition of 2,186 Rite Aid stores and related assets
- antitrust aspects of its $23.8 billion acquisition of the 55% it did not already own of Alliance Boots GmbH, a Switzerland-based international pharmacy-led health and beauty group, and in its previous $6.7 billion purchase of a 45% interest in Alliance Boots